Indaptus TherapeuticsINDP
13F holders, Q4 2025 (December 31)4holders −1
0new positions
1sold out
$2.91avg. 13F price*
At the end of Q4 2025, 4 institutions reported holding Indaptus Therapeutics Inc. (INDP) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were UBS Group AG ($84K), Tower Research Capital LLC (TRC) ($9K) and Bank of America Corp. ($73).
- Company
- Indaptus Therapeutics Inc.
- CUSIP
- 45339J204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $55K |
All 13F filers, Q3 2025 → Q4 2025: 31,178 shares bought and 19,005 shares sold, net +12,173 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | Add +5677.3% | 29,002 | $84K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +566.2% | 3,151 | $9K |
| Bank of America Corp. | 0.00% | Reduce -24.2% | 25 | $73 |
| SBI Securities Co., Ltd. | 0.00% | No change | 17 | $49 |
"% of holder's portfolio" is INDP's weight in each manager's 13F, not the share of Indaptus Therapeutics Inc. the manager owns.